Pharmacotherapy for knee osteoarthritis: current and emerging therapies

被引:90
作者
Cao, Peihua [1 ]
Li, Yamin [1 ]
Tang, Yujin [2 ]
Ding, Changhai [1 ,3 ]
Hunter, David J. [1 ,4 ,5 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Clin Res Ctr, Guangzhou, Guangdong, Peoples R China
[2] Youjiang Med Univ Nationalities, Dept Orthped Surg, Affiliated Hosp, Baise, Guangxi, Peoples R China
[3] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia
[4] Royal North Shore Hosp, Dept Rheumatol, Sydney, NSW, Australia
[5] Univ Sydney, Inst Bone & Joint Res, Kolling Inst, Sydney, NSW, Australia
关键词
Osteoarthritis; disease modification; pain; pharmacotherapy; NERVE GROWTH-FACTOR; TOPICAL DICLOFENAC SODIUM; VITAMIN-D SUPPLEMENTATION; SELECTIVE INOS INHIBITOR; MECHANISM-BASED APPROACH; POST-HOC ANALYSIS; DOUBLE-BLIND; INTRAARTICULAR SPRIFERMIN; CARTILAGE THICKNESS; STRONTIUM RANELATE;
D O I
10.1080/14656566.2020.1732924
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Osteoarthritis (OA) is the leading cause of pain, loss of function and disability in the elderly, with the knee being the most impactful joint affected. Currently, there is still no 'cure' in OA treatment. Areas covered: The authors review the current and emerging therapies for knee OA including traditional OA medications (oral and topical NSAIDs, acetaminophen, and opioids) and emerging treatments including disease-modifying OA drugs. The failures of agents that have been through clinical trials are also summarized. Furthermore, the authors provide their expert perspectives on the future of pharmacotherapy for knee osteoarthritis. Expert opinion: Compared to traditional OA medications, new disease-modifying OA drugs that act by reducing inflammation and increasing cartilage repair show promise to address the unmet need of disease modification. Many of these new drugs, however, are in the preclinical stage. Long-term RCTs are expected to identify the safety and efficacy of novel OA pharmacotherapy medicines.
引用
收藏
页码:797 / 809
页数:13
相关论文
共 124 条
  • [1] Al-Saeed Abdulwahed, 2011, Oman Med J, V26, P385, DOI 10.5001/omj.2011.101
  • [2] Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials
    Avouac, J.
    Gossec, L.
    Dougados, M.
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2007, 15 (08) : 957 - 965
  • [3] Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
    Baker, Darren J.
    Childs, Bennett G.
    Durik, Matej
    Wijers, Melinde E.
    Sieben, Cynthia J.
    Zhong, Jian
    Saltness, Rachel A.
    Jeganathan, Karthik B.
    Verzosa, Grace Casaclang
    Pezeshki, Abdulmohammad
    Khazaie, Khashayarsha
    Miller, Jordan D.
    van Deursen, Jan M.
    [J]. NATURE, 2016, 530 (7589) : 184 - +
  • [4] Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
    Baker, Darren J.
    Wijshake, Tobias
    Tchkonia, Tamar
    LeBrasseur, Nathan K.
    Childs, Bennett G.
    van de Sluis, Bart
    Kirkland, James L.
    van Deursen, Jan M.
    [J]. NATURE, 2011, 479 (7372) : 232 - U112
  • [5] Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data
    Bally, Michele
    Dendukuri, Nandini
    Rich, Benjamin
    Nadeau, Lyne
    Helin-Salmivaara, Arja
    Garbe, Edeltraut
    Brophy, James M.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
  • [6] OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis
    Bannuru, R. R.
    Osani, M. C.
    Vaysbrot, E. E.
    Arden, N. K.
    Bennell, K.
    Bierma-Zeinstra, S. M. A.
    Kraus, V. B.
    Lohmander, L. S.
    Abbott, J. H.
    Bhandari, M.
    Blanco, F. J.
    Espinosa, R.
    Haugen, I. K.
    Lin, J.
    Mandl, L. A.
    Moilanen, E.
    Nakamura, N.
    Snyder-Mackler, L.
    Trojian, T.
    Underwood, M.
    McAlindon, T. E.
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2019, 27 (11) : 1578 - 1589
  • [7] Bassiouni H, 2017, CURR RHEUMATOL REV, V13, P65, DOI 10.2174/1573397112666160404124532
  • [8] The discordance between clinical and radiographic knee osteoarthritis: A systematic search and summary of the literature
    Bedson, John
    Croft, Peter R.
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2008, 9 (1)
  • [9] Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in ostcoarthritic knee pain: meta-analysis of randomised placebo controlled trials
    Bjordal, JM
    Ljunggren, AE
    Klovning, A
    Slordal, L
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7478): : 1317 - 1320D
  • [10] An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
    Bruyere, Olivier
    Honvo, Germain
    Veronese, Nicola
    Arden, Nigel K.
    Branco, Jaime
    Curtis, Elizabeth M.
    Al-Daghri, Nasser M.
    Herrero-Beaumont, Gabriel
    Martel-Pelletier, Johanne
    Pelletier, Jean-Pierre
    Rannou, Francois
    Rizzoli, Rene
    Roth, Roland
    Uebelhart, Daniel
    Cooper, Cyrus
    Reginster, Jean-Yves
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 49 (03) : 337 - 350